Indian govt to increase scrutiny of how drug patents are "worked" domestically
This article was originally published in SRA
Large multinational firms that have been apprehensive about policy initiatives that could expand or regularise compulsory licensing in India may be able to relax for now, as the government says it does not intend to release additional guidelines for the issuance of compulsory licences for medicines1. However, with the government keeping a keen eye on the area, drug firms will have to be more proactive in disclosing how their drug patents are being worked in India.
You may also be interested in...
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.